The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study
Backgrounds and Aims. Elobixibat is a bile acid transporter inhibitor indicated for constipation. Previous studies were performed mainly for the nonelderly and were biased to female. We analyzed the efficacy of elobixibat also for the elderly and male. Materials and Methods. This was a multicenter r...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2020/9656040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565971950239744 |
|---|---|
| author | Akira Tomie Naohisa Yoshida Munehiro Kugai Ryohei Hirose Osamu Dohi Ken Inoue Kotaro Okuda Takayuki Motoyoshi Kohei Fukumoto Yoshikazu Inagaki Hiroyuki Yoriki Yutaka Inada Takashi Okuda Daisuke Hasegawa Kiyoshi Ogiso Takaaki Murakami Koichi Soga Rafiz Abdul Rani Norimasa Yoshida Yoshito Itoh |
| author_facet | Akira Tomie Naohisa Yoshida Munehiro Kugai Ryohei Hirose Osamu Dohi Ken Inoue Kotaro Okuda Takayuki Motoyoshi Kohei Fukumoto Yoshikazu Inagaki Hiroyuki Yoriki Yutaka Inada Takashi Okuda Daisuke Hasegawa Kiyoshi Ogiso Takaaki Murakami Koichi Soga Rafiz Abdul Rani Norimasa Yoshida Yoshito Itoh |
| author_sort | Akira Tomie |
| collection | DOAJ |
| description | Backgrounds and Aims. Elobixibat is a bile acid transporter inhibitor indicated for constipation. Previous studies were performed mainly for the nonelderly and were biased to female. We analyzed the efficacy of elobixibat also for the elderly and male. Materials and Methods. This was a multicenter retrospective cohort study. The subjects were patients aged ≥20 years treated for chronic constipation from May 2018 to November 2019 at 12 related institutions. Patients were divided into ≤74 years and ≥75 years old. Elobixibat at 10 mg/day was prescribed for two weeks. We then analyzed the discontinuation due to ineffectiveness, change of spontaneous bowel movements (SBM), stool consistency, the time until the first SBM, adverse events, and effect-related factors. Results. There were 140 cases (61 males) evaluated, with an average age of 72.1±13.6 years (≤74 years: 71 cases; ≥75 years: 69 cases). The discontinuation rate was 7.9%. The SBM (times/week) increased from 2.86 to 6.08 (p<0.001). The overall SBM improvement rate was 74.0% (≤74 years: 78.2% vs. ≥75 years: 68.9%, p=0.31; male: 75.0% vs. female: 73.3%, p=0.78). The overall improvement rate of stool consistency was 59.6% (≤74 years: 62.9%, ≥75 years: 56.1%, p=0.42). The time until the first SBM (hours) for those ≤74 years and ≥75 years was 17.2±14.3 and 11.2±8.4 (p=0.04). Adverse event rates for those ≤74 years and ≥75 years were 28.2% and 10.1% (p<0.01). There were no significant effect-related factors for gender, age, and use of laxatives. Conclusions. Short-period elobixibat is shown to be effective also for the elderly and male. |
| format | Article |
| id | doaj-art-0b13f55b82c240a9ad39a1d4a7d807ab |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-0b13f55b82c240a9ad39a1d4a7d807ab2025-02-03T01:05:23ZengWileyGastroenterology Research and Practice1687-61211687-630X2020-01-01202010.1155/2020/96560409656040The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort StudyAkira Tomie0Naohisa Yoshida1Munehiro Kugai2Ryohei Hirose3Osamu Dohi4Ken Inoue5Kotaro Okuda6Takayuki Motoyoshi7Kohei Fukumoto8Yoshikazu Inagaki9Hiroyuki Yoriki10Yutaka Inada11Takashi Okuda12Daisuke Hasegawa13Kiyoshi Ogiso14Takaaki Murakami15Koichi Soga16Rafiz Abdul Rani17Norimasa Yoshida18Yoshito Itoh19Department of Gastroenterology, Saiseikai Kyoto Hospital, Kyoto, JapanDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, JapanDepartment of Gastroenterology, Akashi City Hospital, Hyogo, JapanDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, JapanDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, JapanDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, JapanDepartment of Gastroenterology, Kyoto Kujo Hospital, Kyoto, JapanDepartment of Gastroenterology, Kyoto City Hospital, Kyoto, JapanDepartment of Gastroenterology, Nara City Hospital, Nara, JapanDepartment of Gastroenterology, Nishijin Hospital, Kyoto, JapanDepartment of Gastroenterology, Otsu City Hospital, Shiga, JapanDepartment of Gastroenterology, Fukuchiyama City Hospital, Kyoto, JapanDepartment of Gastroenterology, Fukuchiyama City Hospital, Kyoto, JapanDepartment of Gastroenterology, Ayabe City Hospital, Kyoto, JapanDepartment of Gastroenterology, Osaka General Hospital of West Japan Railway Company, Osaka, JapanDepartment of Gastroenterology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center, Kyoto, JapanDepartment of Gastroenterology, Omihachiman Community Medical Center, Shiga, JapanGastroenterology Unit, Faculty of Medicine, Universiti Teknologi MARA, Selangor, MalaysiaDepartment of Gastroenterology, Saiseikai Kyoto Hospital, Kyoto, JapanDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, JapanBackgrounds and Aims. Elobixibat is a bile acid transporter inhibitor indicated for constipation. Previous studies were performed mainly for the nonelderly and were biased to female. We analyzed the efficacy of elobixibat also for the elderly and male. Materials and Methods. This was a multicenter retrospective cohort study. The subjects were patients aged ≥20 years treated for chronic constipation from May 2018 to November 2019 at 12 related institutions. Patients were divided into ≤74 years and ≥75 years old. Elobixibat at 10 mg/day was prescribed for two weeks. We then analyzed the discontinuation due to ineffectiveness, change of spontaneous bowel movements (SBM), stool consistency, the time until the first SBM, adverse events, and effect-related factors. Results. There were 140 cases (61 males) evaluated, with an average age of 72.1±13.6 years (≤74 years: 71 cases; ≥75 years: 69 cases). The discontinuation rate was 7.9%. The SBM (times/week) increased from 2.86 to 6.08 (p<0.001). The overall SBM improvement rate was 74.0% (≤74 years: 78.2% vs. ≥75 years: 68.9%, p=0.31; male: 75.0% vs. female: 73.3%, p=0.78). The overall improvement rate of stool consistency was 59.6% (≤74 years: 62.9%, ≥75 years: 56.1%, p=0.42). The time until the first SBM (hours) for those ≤74 years and ≥75 years was 17.2±14.3 and 11.2±8.4 (p=0.04). Adverse event rates for those ≤74 years and ≥75 years were 28.2% and 10.1% (p<0.01). There were no significant effect-related factors for gender, age, and use of laxatives. Conclusions. Short-period elobixibat is shown to be effective also for the elderly and male.http://dx.doi.org/10.1155/2020/9656040 |
| spellingShingle | Akira Tomie Naohisa Yoshida Munehiro Kugai Ryohei Hirose Osamu Dohi Ken Inoue Kotaro Okuda Takayuki Motoyoshi Kohei Fukumoto Yoshikazu Inagaki Hiroyuki Yoriki Yutaka Inada Takashi Okuda Daisuke Hasegawa Kiyoshi Ogiso Takaaki Murakami Koichi Soga Rafiz Abdul Rani Norimasa Yoshida Yoshito Itoh The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study Gastroenterology Research and Practice |
| title | The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study |
| title_full | The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study |
| title_fullStr | The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study |
| title_full_unstemmed | The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study |
| title_short | The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study |
| title_sort | efficacy and safety of elobixibat for the elderly with chronic constipation a multicenter retrospective cohort study |
| url | http://dx.doi.org/10.1155/2020/9656040 |
| work_keys_str_mv | AT akiratomie theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT naohisayoshida theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT munehirokugai theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT ryoheihirose theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT osamudohi theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT keninoue theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT kotarookuda theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takayukimotoyoshi theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT koheifukumoto theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yoshikazuinagaki theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT hiroyukiyoriki theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yutakainada theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takashiokuda theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT daisukehasegawa theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT kiyoshiogiso theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takaakimurakami theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT koichisoga theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT rafizabdulrani theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT norimasayoshida theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yoshitoitoh theefficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT akiratomie efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT naohisayoshida efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT munehirokugai efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT ryoheihirose efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT osamudohi efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT keninoue efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT kotarookuda efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takayukimotoyoshi efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT koheifukumoto efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yoshikazuinagaki efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT hiroyukiyoriki efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yutakainada efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takashiokuda efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT daisukehasegawa efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT kiyoshiogiso efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT takaakimurakami efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT koichisoga efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT rafizabdulrani efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT norimasayoshida efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy AT yoshitoitoh efficacyandsafetyofelobixibatfortheelderlywithchronicconstipationamulticenterretrospectivecohortstudy |